article thumbnail

Rivus raises $132m to advance clinical development of obesity treatment

Pharmaceutical Technology

The CMAs of the company can lower fat throughout the body through mitochondrial uncoupling, a natural process that causes energy regulation. The post Rivus raises $132m to advance clinical development of obesity treatment appeared first on Pharmaceutical Technology.

article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog

The Clinical Trials Grants Program provides funding for clinical trials that evaluate the safety and efficacy of potential treatments for rare diseases to help move promising treatments through clinical development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NMDA Regulator by Boehringer Ingelheim International for Unspecified Central Nervous System Disorders: Likelihood of Approval

Pharmaceutical Technology

NMDA Regulator is under clinical development by Boehringer Ingelheim International and currently in Phase I for Unspecified Central Nervous System Disorders.

article thumbnail

Global regulators seek permanent working group on AI

pharmaphorum

The International Coalition of Medicines Regulatory Authorities (ICMRA) has recommended that a new permanent working group be set up to keep tabs on the use of AI and make sure that regulations can accommodate new developments. The post Global regulators seek permanent working group on AI appeared first on.

article thumbnail

C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy

Pharmaceutical Technology

According to the deal, C4XD is entitled to get up to $16m in pre-clinical milestone payments before the commencement of the first clinical trial. . on meeting clinical development and commercial milestones in the future, in addition to tiered royalty payments, upon the marketing of the product.

article thumbnail

Interview: Is global AI regulation really revolutionizing pharma and clinical trials?

Outsourcing Pharma

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

article thumbnail

Why Should Companies Use Digital Endpoints Across Clinical Development?

XTalks

Clay is optimistic about the trajectory of DHTs in clinical trials. The field is driven by technological advancements and a stronger consensus among stakeholders — including regulators, patient advocacy groups and trial sponsors — on the importance of patient-centric measures.